# Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol

> **NCT05094609** · PHASE1 · COMPLETED · sponsor: **McMaster University** · enrollment: 36 (actual)

## Conditions studied

- COVID-19
- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** Ad5-triCoV/Mac
- **BIOLOGICAL:** ChAd-triCoV/Mac

## Key facts

- **NCT ID:** NCT05094609
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-03
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094609, "Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05094609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*